Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

(Reuters) -Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the ...

The IPO comes amid a deregulatory push in the energy sector by President Donald Trump, who repeated the "drill, baby, drill" slogan in his inaugural address. Earlier this week, Sean Duffy, the newly ...

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...